Page last updated: 2024-10-24

carbazilquinone and Myelodysplastic Syndromes

carbazilquinone has been researched along with Myelodysplastic Syndromes in 1 studies

Carbazilquinone: An alkylating agent structurally similar to MITOMYCIN and found to be effective in the treatment of leukemia and various other neoplasms in mice. It causes leukemia and thrombocytopenia in almost all human patients.

Myelodysplastic Syndromes: Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.

Research Excerpts

ExcerptRelevanceReference
"A 77-year-old male, who had been treated with carboquone and busulfan for polycythemia vera (PV), developed myelodysplastic syndrome (MDS) 8 years later."3.68[Polycythemia vera terminating in myelodysplastic syndrome]. ( Abe, T; Kimura, S; Kobayashi, Y; Kondo, M; Maruo, N; Ozawa, M; Tanaka, R; Uoshima, N; Yoshida, Y, 1990)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Kimura, S1
Uoshima, N1
Tanaka, R1
Kobayashi, Y1
Ozawa, M1
Maruo, N1
Kondo, M1
Abe, T1
Yoshida, Y1

Other Studies

1 other study available for carbazilquinone and Myelodysplastic Syndromes

ArticleYear
[Polycythemia vera terminating in myelodysplastic syndrome].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 1990, Volume: 31, Issue:1

    Topics: Aged; Busulfan; Carbazilquinone; Humans; Male; Myelodysplastic Syndromes; Polycythemia Vera

1990